Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | FER | P16591 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23752444 | 0.84 | MAPT (0.44) | IDO1MAPTLRRK2LMNAALDH1A1 | |
| SCHEMBL16986622 | 0.84 | CYP1A2 (0.42) | MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL21067503 | 0.84 | TP53 (0.47) | MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL20682565 | 0.80 | DYRK2 (0.50) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL9899738 | 0.80 | IDO1 (0.53) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL6557130 | 0.78 | TSHR (0.50) | L3MBTL1KDM4EGAAGSK3BPDGFRA | |
| SCHEMBL19568178 | 0.78 | TSHR (0.50) | L3MBTL1KDM4EGAAGSK3BPDGFRA | |
| SCHEMBL16566268 | 0.72 | IDO1 (0.44) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL16566110 | 0.72 | IDO1 (0.46) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL7375443 | 0.71 | MAPT (0.49) | IDO1MAPTKDM4EGAAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674839-A1 | NOVEL INDOLINE DERIVATIVE AND USE THEREOF | CK Regeon Inc. (KR) | 2026-01-07 | — | — | EP | disclosed |
| US-12516022-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2024181799-A1 | NOVEL INDOLINE DERIVATIVE AND USE THEREOF | 주식회사 씨케이리제온 | 2024-09-06 | — | — | WO | disclosed |
| US-20240182416-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240010635-A1 | NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF | Pelemed Co., Ltd. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4253385-A1 | NOVEL INDIRUBIN DERIVATIVE HAVING HETEROBICYCLIC RESIDUE AND USE THEREOF | Pelemed Co., Ltd. (KR) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023153630-A1 | NOVEL INDIRUBIN DERIVATIVE HAVING HETEROBICYCLIC RESIDUE AND USE THEREOF | 주식회사 펠레메드 | 2023-08-17 | — | — | WO | disclosed |
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20200345645-A1 | COMPOSITIONS COMPRISING INDIGO AND/OR AN INDIGO DERIVATIVE AND METHODS OF USE THEREOF | AZORA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2014053580-A1 | ANTICONVULSANT ACTIVITY OF GSK-3BETA INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-04-10 | — | — | WO | disclosed |
| WO-2012078519-A2 | 3-ACYLIDENE-2-OXOINDOLE DERIVATIVES FOR INHIBITION OF TRANSGLUTAMINASE 2 | NUMERATE, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AHR, ARNT, NR4A1 | IDO1 827/4885MAPT 811/4885L3MBTL1 2681/4885 |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | IDO1 827/4885MAPT 811/4885L3MBTL1 2681/4885 |
| US-20240010635-A1 | NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF | FLT3, RET, FER | IDO1 429/4885MAPT 3602/4885L3MBTL1 656/4885 |
| US-20240182416-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AHR, ARNT, NR4A1 | IDO1 827/4885MAPT 811/4885L3MBTL1 2681/4885 |
| US-20200345645-A1 | COMPOSITIONS COMPRISING INDIGO AND/OR AN INDIGO DERIVATIVE AND METHODS OF USE THEREOF | AHR, ARNT, IDO1 | IDO1 3/4885MAPT 1540/4885L3MBTL1 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.